Biogen Idec Increases Profits But Misses 4Q EPS Estimates
BioWorld Online - Atlanta,GA,USA
The perception that sales are lagging for its flagship product, the multiple sclerosis drug Avonex (interferon beta-1a), played a role in investors' jitters ...
See all stories on this topic